Carnitine supplementation for valproate-related hyperammonemia to maintain therapeutic valproate level

Journal of Clinical Psychopharmacology

Volumn 31, Issue 5, 2011, Pages 680-682

  Sonik, Priya ^a   Hilty, Donald M ^b   Rossaro, Lorenzo ^c   Bourgeois, James A ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; BENZATROPINE; CARNITINE; HALOPERIDOL; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ADULT; AMMONIA BLOOD LEVEL; BEDTIME DOSAGE; CASE REPORT; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; HUMAN; HYPERAMMONEMIA; LABORATORY TEST; LETTER; LIVER FUNCTION TEST; MALE; MINI MENTAL STATE EXAMINATION; MORNING DOSAGE; PRIORITY JOURNAL; PSYCHOPATHY; SCHIZOPHRENIA; SCREENING; TREATMENT OUTCOME;

ADULT; ANTICONVULSANTS; ANTISOCIAL PERSONALITY DISORDER; CARNITINE; HUMANS; HYPERAMMONEMIA; MALE; SCHIZOPHRENIA; VALPROIC ACID; VITAMIN B COMPLEX;

EID: 80052463564     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31822cd2a0     Document Type: Letter

References (6)

1. McCall M, Bourgeois JA. Valproic acid-induced hyperammonemia. A case report. J Clin Psychopharmacol. 2004; 24(5):521-526. (Pubitemid 39274206)
2. Lheureux PER, Penaloza A, Zahir S, et al. Science review: carnitine in the treatment of valproic acid-induced toxicityVwhat is the evidence? Crit Care. 2005;9:431-440. (Pubitemid 41498538)
3. Verrotti A, Trotta D, Morgese G, et al. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis. 2002;17(4):367-373. (Pubitemid 36204766)
4. Watanabe A, Sakai T, Sato S, et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology. 1997;26(6): 1410-1414. (Pubitemid 27520004)
5. AACE Nutrition Guidelines Task Force: American Association of Clinical Use of Dietary Supplements and Nutraceuticals. Endocr Pract. 2003;9:417-470.
6. Carlson T, Reynold CA, Caplan R. Case report: valproic acid and risperidone treatment leading to development of hyperammonemia and mania. J Am Acad Child Adolesc Psychiatry. 2007;46(3):356-361.